Company News

Polaris Pharmaceuticals applies for the first listing

Polaris Group Polaris Pharmaceuticals – KY (6550TW) rush to the stock exchange to apply for the first listing of shares before the end of 2021! Polaris Pharmaceutical-KY submitted an application for listing on the 27th. It is the second foreign company to apply for the first listing in this (2021) year. .

The person in charge of Polaris Pharmaceutical-KY Company is Howard Chen, and the actual operating entities include: Polaris Pharmaceuticals, Inc., DesignRx Pharmaceuticals, Inc., DesignRx Pharmaceuticals (Chengdu) Company and Taipei TDW New Drug Research and Development Company; the host underwriter is Cathay Securities Corporation.

Polaris Pharmaceuticals-KY application paid-in capital/net value were 4.118 billion TWD (excluding private equity of 3.07 billion TWD)/7.402 billion TWD; main products include new drug R&D and manufacturing; last (2020) year pre-tax net loss of 6.6 100 million TWD, the after-tax loss per share was 1.01 TWD, and the loss per share in the first half of this year was 0.54 TWD.

Scroll to Top
This site is registered on as a development site.